Celularity invests $2.9M in Defeye preferred stock; gets Nasdaq extension to Aug 31 for late filings

Celularity Inc

Acquired 7,198.6 shares of Defeye Series Seed-2 Preferred Stock for $2.89M in product purchase credits.
Received Nasdaq notice of non-compliance for late Q1 2025 10-Q filing; submitted compliance plan.
Nasdaq extended deadline to Aug 31, 2025 to file both Q1 and Q2 10-Qs; risk of delisting if missed.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.